Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Biodexa Pharmaceuticals plc American Depositary Shs · BDRX

BDRXNASDAQotherCurrentCIK 1643918Updated Nov 16, 2026

Company: Biodexa Pharmaceuticals Plc →

Name history
Midatech Pharma Plc · through Mar 27, 2023

BDRX price & chart

Provider market data

Loading TradingView…

NASDAQ:BDRX on TradingView ↗

TradingView · Data may be delayed

About the company

We are a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including gastrointestinal stromal tumors (“GIST”), familial adenomatous polyposis (“FAP”), non-muscle invasive bladder cancer (“NMIBC”), and type 1 diabetes (“T1D”).

F-1 · 2026-09-24 · 0001214659-26-011934

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 6-K filing

    6-K · 2026-11-09 · 0001171843-26-007261

  2. 6-K filing

    6-K · 2026-10-14 · 0001171843-26-006616

  3. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012864

  4. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012866

  5. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012868

Show 5 more recent filings
  1. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012870

  2. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012867

  3. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012869

  4. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012865

  5. 424B3 filing

    424B3 · 2026-10-14 · 0001214659-26-012871

Financials

FY 2025 · GBP
Revenue— · FY 2025
Net income— · FY 2025
Assets—GBP · FY 2025
Cash— · FY 2025
Operating income-8,645,000GBP · FY 2025
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

Diluted EPS-0GBP/shares · FY 2025
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossGBP-6,384,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-5,729,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-7,079,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-7,656,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForDecreaseIncreaseInTradeAccountReceivableGBP2,629,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-5,975,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

365,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

7,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

AdjustmentsForIncomeTaxExpenseGBP-105,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-250,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-406,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-832,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP-913,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

2,239,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-207,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

356,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

AdjustmentsForSharebasedPaymentsGBP170,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

283,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

28,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

123,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP343,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-93,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

164,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

9,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP-707,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-129,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-845,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-678,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsFinancingActivitiesGBP14,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

—13,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

18,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP———178,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

ProceedsFromIssuingSharesGBP13,749,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

8,312,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

10,427,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

243,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Total RevenueGBP——381,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

699,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

Additional Financial Items
AdministrativeExpenseGBP4,836,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

3,793,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

4,342,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

4,542,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareGBP/shares-0
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-0
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

——
DepreciationRightofuseAssetsGBP136,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

135,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

137,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

166,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareGBP/shares-0
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-0
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

——
FinanceCostsGBP229,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

165,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

41,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

53,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

FinanceIncomeGBP2,385,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

3,385,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

570,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

497,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsGBP-105,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-250,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-406,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-832,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesGBP10,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

19,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

28,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

43,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

OtherIncomeGBP152,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

31,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

14,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

22,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

PostemploymentBenefitExpenseDefinedContributionPlansGBP69,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

67,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

86,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

98,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxGBP-6,489,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-5,979,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-7,485,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-8,488,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesGBP-8,645,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

-9,199,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

-8,014,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

-8,932,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseGBP3,961,000
Source

20-F · 2026-03-27 · 0001214659-26-003921

2025-01-01 to 2025-12-31

5,437,000
Source

20-F · 2025-04-11 · 0001214659-25-005742

2024-01-01 to 2024-12-31

4,067,000
Source

20-F · 2024-04-19 · 0001214659-24-007125

2023-01-01 to 2023-12-31

5,111,000
Source

20-F · 2023-04-28 · 0001214659-23-006169

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-299106

F-1 · 2026-09-24 · 0001214659-26-011934

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-297473

F-1/A · 2026-07-30 · 0001214659-26-009176

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ex4_1.htm · 6-K · 2026-09-15

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUAN…

6-K · 2026-09-15 · 0001214659-26-011688

Read attachment ↗
ex99_1.htm · 6-K · 2026-09-15

Exhibit 99.1 Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an …

6-K · 2026-09-15 · 0001214659-26-011688

Read attachment ↗
ex99_1.htm · 6-K · 2026-09-11

Exhibit 99.1 BIODEXA PHARMACEUTICALS PLC INTERIM RESULTS This interim financial information is being furnished under form 6-K Six months ended June 30, 2026 1 September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today annou…

6-K · 2026-09-11 · 0001214659-26-011630

Read attachment ↗
ex4_1.htm · F-1/A · 2026-07-30

EX-4.1 3 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …

F-1/A · 2026-07-30 · 0001214659-26-009176

Read attachment ↗
ex99_1.htm · 6-K · 2026-07-29

Exhibit 99.1 July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company’s shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at…

6-K · 2026-07-29 · 0001214659-26-009162

Read attachment ↗
ex4_1.htm · F-1 · 2026-07-15

EX-4.1 2 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …

F-1 · 2026-07-15 · 0001214659-26-008591

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.